Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
ORGANIZATION
Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
Shipment restrictions had been lifted for only 49 products as of the end of December following the Japanese health ministry’s request to remove such measures for 130 APIs/specifications, according to an industry survey. This is 7.6% of 646 products containing…
To read the full story
Related Article
- FPMAJ Investigating Supply Status for 60% of All Drugs, Tally Due Out by Year-End
September 14, 2022
- Shipment Curbs Remain for Over 40% of Drugs Despite Sufficient Supply Volumes: FPMAJ Survey
June 24, 2022
- MHLW Publishes Brand-by-Brand Supply Status for 130 APIs Subject to Its Restriction Lifting Request
March 9, 2022
- FPMAJ Begins Survey on Lifting of Shipment Restrictions
February 24, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
- MHLW Sets Volume Thresholds for Drug Orders to Resolve Generic Shortages
January 28, 2022
- MHLW Eyes Information Provisioning on Generic Supplies by Individual Brands
December 24, 2021
- Generic Makers Scrambling to Respond to MHLW Request to Lift Shipment Restrictions, Wholesalers Fret Further Confusion
December 15, 2021
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
ORGANIZATION
- Rethink Labor Cost Calculations in Drug Pricing: Pharma Labor Group
November 5, 2026
- Medipal’s Choufuku Takes Over as JPWA Vice Chair
November 4, 2026
- Enhertu, Dupixent Win 2026 International Prix Galien Biotechnology Award
November 2, 2026
- Pharma Trade Groups Flag Potential Leak of 30,000 Email Addresses
November 2, 2026
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…